Skip to main content
TipRanks
Go Ultimate75% OFF

Anika Therapeutics (AKP) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

AKP Analyst Ratings

Moderate Buy
2Ratings
2Buy0Hold0Sell
Based on 2 analysts giving stock ratings to Anika Therapeutics in the past 3 months

AKP Stock 12 Month Forecast

€20.63▲(76.28% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Anika Therapeutics in the last 3 months. The average price target is EUR 20.63 with a high forecast of EUR 20.63 and a low forecast of EUR 20.63. The average price target represents a 76.28% change from the last price of EUR 11.70.
Highest Price Target€20.63Average Price Target€20.63Lowest Price Target€20.63

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:AKP
Price TargetArticle
Barrington€20.63buy76.28%UpsideReiterated11/09/26
B. Riley Securities€18.83→€20.63buy76.28%UpsideInitiated09/18/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
DFTXDefinium Therapeutics
RDNTRadnet
AXGNAxoGen
PLSEPulse Biosciences
AHCOAdaptHealth

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Anika Therapeutics

3 Months
Michael Petusky
Michael PetuskyBarrington
Success Rate18/28 ratings generated profit
64%
Average Return
+0.84%

Copying Michael Petusky's trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +0.84% per trade.

1 Year
Michael Petusky
Michael PetuskyBarrington
Success Rate9/28 ratings generated profit
32%
Average Return
-6.72%

Copying Michael Petusky's trades and holding each position for 1 Year would result in 32.14% of your transactions generating a profit, with an average return of -6.72% per trade.

2 Years
Michael Petusky
Michael PetuskyBarrington
Success Rate8/28 ratings generated profit
29%
Average Return
-13.77%

Copying Michael Petusky's trades and holding each position for 2 Years would result in 28.57% of your transactions generating a profit, with an average return of -13.77% per trade.

AKP Analyst Recommendation Trends

01234Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for AKP
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy00001
Buy22333
Hold00000
Sell00000
Strong Sell00000
total22334

In the current month, AKP has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AKP average Analyst price target in the past 3 months is 20.63.

AKP Financial Forecast

€-1€-0.5€0€0.5€1Q1 2026Q3 2026Q4 2026
High€0.12
Consensus€0.12
Low€0.12

AKP Earnings Forecast

Next quarter’s earnings estimate for AKP is EUR 0.12 with a range of EUR 0.12 to EUR 0.12. The previous quarter’s EPS was EUR 0.26. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

€26.5M€27.2M€27.9M€28.5M€29.2MQ1 2026Q3 2026Q4 2026
High€26.6M
Consensus€26.6M
Low€26.5M

AKP Sales Forecast

Next quarter’s sales forecast for AKP is EUR 26.57M with a range of EUR 26.55M to EUR 26.59M. The previous quarter’s sales results were EUR 27.39M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

AKP Stock Forecast FAQ

What is DE:AKP’s average 12-month price target, according to analysts?
Based on analyst ratings, Anika Therapeutics’s 12-month average price target is €20.63.
What is DE:AKP’s upside potential, based on the analysts’ average price target?
Anika Therapeutics has 76.28% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Anika Therapeutics a Buy, Sell or Hold?
Anika Therapeutics has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Anika Therapeutics’s share price target?
The average share price target for Anika Therapeutics is €20.63. This is based on 2 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €20.63, and the lowest forecast is €20.63. The average share price target represents a 76.28% increase from the current price of €11.7.
What do analysts say about Anika Therapeutics?
Anika Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Street analysts.
How can I buy shares of Anika Therapeutics?
To buy shares of DE:AKP, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.